The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 47 of the 72 sources its claims cite were checked for support.
Targeting TBK1 to overcome resistance to cancer immunotherapy
Open accessAbstract
Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1,2. Here we identify the innate immune kinase TANK-binding kinase 1 (TBK1)3 as a candidate immune-evasion gene in a pooled genetic screen 4. Using a suite of genetic and pharmacological tools across multiple experimental model systems, we confirm a role for TBK1 as an immune-evasion gene. Targeting TBK1 enhances responses to PD-1 blockade by decreasing the cytotoxicity threshold to effector cytokines (TNF and IFNγ). TBK1 inhibition in combination with PD-1 blockade also demonstrated efficacy using patient-derived tumour models, with concordant findings in matched patient-derived organotypic tumour spheroids and matched patient-derived organoids. Tumour cells lacking TBK1 are primed to undergo RIPK- and caspase-dependent cell death in response to TNF and IFNγ in a JAK-STAT-dependent manner. Taken together, our results demonstrate that targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.
Overview
CoChat Summary
TL;DR
TBK1 is identified as a tumour-intrinsic immune evasion kinase, and genetic or pharmacologic TBK1 inhibition sensitizes tumours to PD-1 blockade by lowering the threshold for TNFα/IFNγ-induced RIPK- and caspase-dependent cell death. In murine and patient-derived models, TBK1 inhibition plus PD-1 blockade improved tumour control, including in immunotherapy-resistant melanoma.
Key findings
- In B16 melanoma, Tbk1 sgRNAs were depleted after PD-1 blockade; Tbk1-null tumours grew comparably to controls in immunodeficient NSG and wild-type mice but showed improved tumour shrinkage and survival with anti-PD-1. TBK1i plus anti-PD-1 improved tumour control in B16-ova, D4M.3A, acquired-resistant B16-ova MDOTS, MC38, and MB49 models.
- In patient-derived organotypic tumour spheroids (PDOTS; n=30: cutaneous melanoma n=15, non-cutaneous melanoma n=2, other cancers n=13), response rates were 30% for TBK1i, 40% for TBK1i plus PD-1 blockade, and 16.6% for single-agent PD-1 blockade. Responses occurred in immunotherapy-resistant metastatic cutaneous melanoma and MSI colorectal carcinoma.
- Single-cell RNA-seq of CD45+ cells (n=53,637) from B16-ova tumours showed TBK1i ± anti-PD-1 expanded myeloid cells, pro-inflammatory macrophages, and early exhausted/effector CD8+ T cells, while reducing terminal exhausted/effector CD8+ T cells and MDSCs; Tnf and Il1a were enhanced. Tbk1-null tumours showed limited immune remodeling by scRNA-seq (n=31,810 CD45+ cells).
- Tbk1-null B16 cells were sensitive to combined TNFα/IFNγ but not either cytokine alone; death required RIPK and caspase signaling and intact IFNγ/JAK-STAT sensing, while STING and IRF3 were dispensable. TBK1i lowered the cytotoxic threshold to TNFα/IFNγ in A375 melanoma cells, PDOTS, and matched patient-derived organoids.
Methods
- Pooled CRISPR-Cas9 screens were performed in vivo in B16 melanoma and in vitro in control and Tbk1-null B16 cells challenged with TNFα/IFNγ. Validation used syngeneic murine tumour models (B16, B16-ova, CT26, D4M.3A, MC38, MB49), murine-derived organotypic tumour spheroids (MDOTS), and pharmacologic TBK1 inhibitors.
- Patient-derived PDOTS and PDOs from melanoma and other cancers were cultured ex vivo in 3D microfluidic devices or Matrigel with anti-PD-1, TBK1i, and/or cytokines; viability was assessed by fluorescence live/dead staining or CellTiter-Glo. Additional analyses included scRNA-seq of CD45+ tumour-infiltrating cells, Olink plasma proteomics in metastatic melanoma patients, growth rate inhibition metrics, immunoblotting, flow cytometry, and qRT-PCR.
Limitations
- Stated: future studies are required to deconvolute the roles of TBK1 in distinct immune cell populations and to determine the therapeutic potential of disrupting TBK1 signaling in melanoma patients resistant to immunotherapy. The paper also states that murine models lack the heterogeneity of human cancer, while patient-derived models are heterogeneous and more complex.
- Stated/evident: animal studies did not use statistical methods to predetermine sample size, used at least five mice per group, and no blinding was performed; TBK1i in vivo studies also state that investigators were not blinded to treatment groups.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 1 Not valid · 11 Not checked · 127 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
What the sources say
- Supportedcites [14] Jenkins, R. W. et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8, 196–215 (2018). source
The citation is attached to the term MDOTS, identifying the ex vivo profiling method rather than attributing the citing paper’s B16-ova combination result to Jenkins et al. The Results section describes isolating murine-derived organotypic tumor spheroids and testing them in 3D microfluidic culture; it also reports enhanced killing with PD-1 blockade plus a TBK1/IKKε inhibitor in CT26 MDOTS. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our findings with RIPK1, treatment with small molecule inhibitors of RIPK3 (HS-1371) 38 or MLKL (GW806742X) 39 rescued Tbk1-null B16 cells from TNF α /IFN γ -induced cell death when combined with caspase inhibition (Extended Data Fig. 8d-e).”
What the sources say
- Supportedcites [38] Park, H.-H. et al. HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis. Exp. Mol. Med. 50, 1–15 (2018). source
Citation 38 identifies HS-1371 as a small-molecule RIPK3 inhibitor. The Results section (‘HS-1371 blocks RIP3 kinase activity’) states that HS-1371 potently inhibits RIP3 kinase activity. The Tbk1-null B16 rescue result is presented as the citing authors’ own finding, not as a result attributed to this source. (LLM, conf=0.94)
- Partly supportedcites [39] Hildebrand, J. M. et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl Acad. Sci. USA 111, 15072–15077 (2014). sourceExperimental — accuracy not yet measured
Citation 39 is attached to the identification of GW806742X as an MLKL inhibitor, not to the citing authors’ B16-cell result. The source’s Results report that an MLKL-binding molecule called “compound 1” inhibited necroptotic death in mouse dermal fibroblasts, but our copy does not identify it as GW806742X. It therefore supports the inhibitor description, not the specific compound identification. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“BCL2-homology domain (BH3) profiling 41 demonstrated that cytochrome c release following mitochondrial exposure to pro-apoptotic BH3-only peptides (e.g. BIM BH3, PUMA BH3) was similar in control and Tbk1-null B16 cells (Extended Data Fig. 9a).”
What the sources say
- Supportedcites [41] Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977–989 (2015). source
Citation 41 identifies the BH3-profiling method, which the source describes in its Introduction and Dynamic BH3 Profiling procedures. The comparison between control and Tbk1-null B16 cells is presented as the citing paper’s own result (Extended Data Fig. 9a), not as a finding attributed to this source. (LLM, conf=0.92)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, TBK1 has an emerging role in regulating death receptor signaling distinct from its role in innate immune response and viral sensing 35,36,49 .”
What the sources say
- Supportedcites [35] Lafont, E. et al. TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 20, 1389–1399 (2018). source
The Introduction identifies a TBK1/IKKε function in TNF signaling that restricts cell death, alongside their established role in interferon signaling after viral infection. The Discussion describes this cell-death checkpoint as a newly identified role. Page numbers are not available in the supplied passages. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [36] Xu, D. et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 174, 1477–1491 (2018). source
- Supportedcites [49] Taft, J. et al. Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell 184, 4447–4463 (2021). source
The Introduction contrasts TBK1’s classical role in innate immune signaling with its more recently recognized role in negatively regulating TNF-mediated cell death through RIPK1. The Results section on TNF-driven RIPK1-mediated cell death further shows that TBK1 deficiency increases TNF-induced cell death, supporting a role in death-receptor signaling distinct from antiviral signaling. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
What the sources say
- Supportedcites [14] Jenkins, R. W. et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8, 196–215 (2018). source
The Results report that, in mice bearing CT26 tumors, combined TBK1/IKKε inhibition and anti-PD-L1 produced greater tumor control and longer survival than either treatment alone. The Discussion describes this as in vivo efficacy of a combination that enhances response to PD-1 blockade. (LLM, conf=0.94)
- Supportedcites [15] Zhu, L. et al. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat. Cell Biol. 21, 1604–1614 (2019). source
The Results section, “Pharmacological inhibition of TBK1 suppresses tumor growth and promotes antitumor immunity” (Fig. 6b,c), reports that anti-CTLA4 alone did not significantly reduce tumour burden in KrasLA2 mice, but did so when combined with the TBK1 inhibitor amlexanox. This supports the claim of early promise for enhancing response to immune checkpoint blockade in a murine tumour model. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
77 more claims · 7 with their cited sources checked
Create a free account to see all 166 claims and to verify the 7 references still open.
- Probably not a substantial claim. 41
- It may state two separate claims as one. 52
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Organotypic tumour spheroid preparation and microfluidic culture. · p. 16
“passed over 100 mm and 40 mm filters sequentially”
§ Organotypic tumour spheroid preparation and microfluidic culture. · p. 16
“S1 (>100 μm), S2 (40-100 μm), and S3 (<40 μm) spheroid fractions”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TBK1 restrains necroptosis · p. 8
“Increased levels of p-RIPK1 (S166/T189) were observed in Tbk1-null B16 within 3 hours of TNF α /IFN γ treatment”
§ Antibodies. · p. 21
“primary antibodies against TBK1 (#ab40676, Abcam), IKK ε (#3416T, Cell Signaling), p-RIPK S166/T169 (#31122S, Cell Signaling)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Analysis of tumour-infiltrating immune cells by single cell RNA-seq. · p. 15
“For tumour-specific TBK1 CRISPR studies, Tbk1-null (sgRNA-2) or control sgRNA-1 B16 tumour cells (2 × 10 6 ) were implanted in Matrigel into the stomach of C57BL/6 female mice.”
§ Analysis of tumour-infiltrating immune cells by single cell RNA-seq. · p. 15
“Four representative samples each of Tbk1-null (sgRNA-1) or control sgRNA-1 samples were selected, counted, and loaded onto the Chromium Controller (10X Genomics).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ References · p. 46
“d , Tumour volume analysis of mice bearing B16-ova tumours treated with TBK1i (Compound 1, 40mg/kg daily by oral gavage), α PD-1 (200 mg i.p. tiw x 6 doses), or combination”
§ Animal treatment and tumour challenges. · p. 12
“isotype control IgG (#BE0089, clone 2A3, BioXCell) or anti-PD-1 (#BP0273, BioXCell, clone: 29F.1A12) (10 mg/kg) was administered three times weekly for a total of six doses.”
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Self-citationSTING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Cited by
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
“In addition, targeting TBK1 can overcome ICB resistance in PDOTS from patients with metastatic cutaneous melanoma and patients with microsatellite instability (MSI)-high CRC 150 .”
InfluentialWang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 122
“The role of TBK1 as an immune-evasion gene has been elucidated, revealing that its inhibition can augment the response to PD-1 blockade therapy and sensitise T-cell immune effector functions [136].”
BackgroundA Review of Current and Pipeline Drugs for Treatment of Melanoma
Natarelli, N., Aleman, S. J., Mark, I. M., Tran, J. T., Kwak, S., Botto, E., Aflatooni, S., Diaz, M. J., & Lipner, S. R. (2024) · Pharmaceuticals · doi:10.3390/ph17020214 · Cited by 107
“This inhibition could overcome the resistance to the PD-blockade [37].”
BackgroundPan-cancer proteogenomics characterization of tumor immunity
Petralia, F., Ma, W., Yaron, T. M., Caruso, F. P., Tignor, N. L., Wang, J. M., Charytonowicz, D., Johnson, J. L., Huntsman, E. M., Marino, G. B., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.027 · Cited by 112
Metadata
- Authors
- Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., Fu, A., Ma, X., Gwee, J., Tiwari, P., Du, P. P., Sindurakar, P., Tian, J., Mehta, A., Schneider, A. M., Yizhak, K., Sade-Feldman, M., LaSalle, T., Sharova, T., Xie, H., Liu, S., Michaud, W. A., Saad-Beretta, R., Yates, K. B., Iracheta-Vellve, A., Spetz, J. K. E., Qin, X., Sarosiek, K. A., Zhang, G., Kim, J. W., Su, M. Y., Cicerchia, A. M., Rasmussen, M. Q., Klempner, S. J., Juric, D., Pai, S. I., Miller, D. M., Giobbie-Hurder, A., Chen, J. H., Pelka, K., Frederick, D. T., Stinson, S., Ivanova, E., Aref, A. R., Paweletz, C. P., Barbie, D. A., Sen, D. R., Fisher, D. E., Corcoran, R. B., Hacohen, N., Sorger, P. K., Flaherty, K. T., Boland, G. M., Manguso, R. T., & Jenkins, R. W.
- Affiliations
- Harvard University (US)
- Broad Institute (US)
- Technion – Israel Institute of Technology (IL)
- The Wistar Institute (US)
- University of California San Diego (US)
- Gilead Sciences (United States) (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Jenkins, Russell W.
- ORCID
- Sun, Yi
- Revach, Or-yam
- Anderson, Seth
- Kessler, Emily A.
- Wolfe, Clara H.
- Jenney, Anne
- Mills, Caitlin E.
- Robitschek, Emily J.
- Kim, Sarah
- Fu, Amina
- Ma, Xiang
- Gwee, Jia
- Tiwari, Payal
- Du, Peter P.
- Mehta, Arnav
- Schneider, Alexis M.
- Yizhak, Keren
- Sade-Feldman, Moshe
- LaSalle, Thomas
- Sharova, Tatyana
- Xie, Hongyan
- Liu, Shuming
- Michaud, William A.
- Yates, Kathleen B.
- Iracheta-Vellve, Arvin
- Spetz, Johan K. E.
- Qin, Xingping
- Sarosiek, Kristopher A.
- Zhang, Gao
- Su, Mack Y.
- Cicerchia, Angelina M.
- Rasmussen, Martin Q.
- Klempner, Samuel J.
- Juric, Dejan
- Pai, Sara I.
- Miller, David M.
- Chen, Jonathan H.
- Pelka, Karin
- Frederick, Dennie T.
- Ivanova, Elena
- Aref, Amir R.
- Paweletz, Cloud P.
- Barbie, David A.
- Sen, Debattama R.
- Fisher, David E.
- Corcoran, Ryan B.
- Hacohen, Nir
- Sorger, Peter K.
- Flaherty, Keith T.
- Boland, Genevieve M.
- Manguso, Robert T.
- Jenkins, Russell W.
- Venue
- Nature
- Published
- 2023-01-12
- Volume
- 615
- Issue
- 7950
- Pages
- 158-167
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC10171827
- OpenAlex
- W4315784559
- Cited by
- 174
- References
- 73
- Citations by year
- 2026: 33 · 2025: 61 · 2024: 53 · 2023: 26
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.86371)
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Stand Up To Cancer
- National Cancer Institute (K08CA226391, R01CA222871, K99CA259511, T32CA207021, P01CA240239, R37CA248565, P01CA163222)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125263)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR072304, R01AR043369)
- National Institute of Dental and Craniofacial Research (U01DE033324)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TBK1, cancer immunotherapy resistance, anti-PD-1 therapy, immune evasion, innate immune signaling, TNF-α, interferon-gamma, JAK/STAT signaling, caspase-dependent cell death, kinase inhibition
- MeSH terms
- Humans, Immunotherapy, Interferon-gamma, Organoids, Protein Serine-Threonine Kinases, Spheroids, Cellular, Drug Resistance, Neoplasm, Caspases, Tumor Necrosis Factors, STAT Transcription Factors, Janus Kinases, Immune Evasion, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting TBK1 to overcome resistance to cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41586-023-05704-6
- The paper
- Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., Fu, A., Ma, X., Gwee, J., Tiwari, P., Du, P. P., Sindurakar, P., Tian, J., Mehta, A., Schneider, A. M., . . . Jenkins, R. W. (2023). Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. https://doi.org/10.1038/s41586-023-05704-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.